CatalystFDA/Bio

PROTAGONIST THERAPEUTICS, INC. (PTGX) DISCUSSES FDA APPROVAL OF MIMRYLO FOR ERYTHROCYTOSIS IN POLYCYTHEMIA VERA TRANSCRIPT - SEEKINGALPHA

FDA approval of Mimrylo for polycythemia vera erythrocytosis is a major regulatory catalyst for PTGX.

What changed

FDA approval of Mimrylo for polycythemia vera erythrocytosis is a major regulatory catalyst for PTGX.

Why it matters

FDA approval of Mimrylo for polycythemia vera erythrocytosis is a major regulatory catalyst for PTGX. — impact context not separately stored; see What changed.

Sources

seekingalpha